Blue Jet Healthcare Limited has scheduled an analyst and investor conference call to discuss its financial performance for the third quarter and nine months of fiscal year 2026. The pharmaceutical company announced the earnings call through a regulatory filing under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Earnings Call Details

The conference call is scheduled to discuss the company's unaudited standalone financial results for the quarter and nine months ended December 31, 2025. Company Secretary and Compliance Officer Sweta Poddar signed the regulatory intimation on February 6, 2026.

Management Participation

The earnings call will feature key members of Blue Jet Healthcare's senior management team who will present the financial results and address questions from analysts and investors.

Company Profile

Blue Jet Healthcare Limited operates as a specialty pharmaceutical and healthcare ingredient company under a contract development and manufacturing organization (CDMO) business model. The company has developed specialized chemistry capabilities in two key areas: contrast media intermediates and high-intensity sweeteners.

The company has established long-term relationships with innovator and multinational generic pharmaceutical companies, supported by multi-year contracts. Blue Jet Healthcare supplies critical starting intermediates and advanced intermediates to three of the world's largest contrast media manufacturers, including GE Healthcare, Guerbet, and Bracco. Additionally, the company provides high-intensity sweeteners to multinational companies such as Colgate Palmolive India Limited and Unilever.

Contact Information

For further details regarding the earnings call, stakeholders can contact Company Secretary Sweta Poddar at companysecretary@bluejethealthcare.com . Investor relations support is provided by EY Investor Relations through Diwakar Pingle and Kunal Bhoite. Participants are advised to dial in 10 minutes before the scheduled call time.

Blue Jet Healthcare Limited has received a CARE A1+ Stable/CARE A1+ credit rating from CARE Ratings Limited for its bank facilities worth ₹275.00 crore. The company announced this development through a regulatory filing under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Credit Rating Details

CARE Ratings has assigned the following rating to Blue Jet Healthcare Limited:

The rating assignment reflects the company's strong financial profile and established market position in the pharmaceutical intermediates sector.

Key Rating Strengths

The rating derives strength from several factors including the company's established operational track record spanning over five decades in contrast media, high-intensity sweeteners, and pharmaceutical intermediates. Blue Jet Healthcare operates through two sites with eight manufacturing blocks accredited by global regulatory bodies including ISO, WHO-GMP, SMETA, and FSSAI.

Financial Performance Highlights

The company demonstrated strong financial performance in recent years:

The improvement in profitability margins is primarily attributed to the addition of CDMO services for global innovators, particularly in Bempedoic Acid intermediates used for cholesterol management.

Business Profile and Market Position

Blue Jet Healthcare has established itself as a leading Indian manufacturer of contrast media intermediates with a portfolio of 20 commercialized molecules used across MRI, CT, and X-ray diagnostics. The company exports to 50+ countries and derives 87% of its revenue from international markets, maintaining customer relationships ranging from 4 to 26 years.

Product Portfolio Diversification

Rating Constraints and Risk Factors

Despite the positive rating, CARE Ratings highlighted several constraints including high customer and product concentration, with 79% of revenue contributed by top 5 customers in FY25. The company's working capital-intensive operations show gross current asset days of 333 days in FY25, driven by longer export receivables of 92 days and inventory holding requirements of 114 days.

Capital Expansion Plans

Blue Jet Healthcare has outlined a capital expenditure plan of ₹1,300 crore over the next 3-4 years for capacity expansion, product development, backward integration, and establishing an R&D centre. The execution and stabilization risks associated with these expansion plans remain key rating sensitivities.

Financial Risk Profile

The company maintains a comfortable capital structure with overall gearing of 0.02x as of March 31, 2025, compared to nil as of March 31, 2024. CARE Ratings noted the company's strong liquidity position with liquid investments of ₹269.81 crore, including cash and bank balances of ₹98.12 crore and debt mutual funds of ₹171.69 crore.

Outlook and Rating Sensitivities

The stable outlook reflects CARE Ratings' expectation that Blue Jet Healthcare will maintain its established market position supported by its diversified product portfolio and long-term customer relationships. Positive rating factors include significant growth in scale of operations above ₹1,700 crore while maintaining current profitability levels, while negative factors include non-renewal of long-term contracts leading to decline in TOI below ₹800 crore or significant moderation in operating profitability.